This year, the U.S. Supreme Court issued two significant opinions that will impact patent protection in the life sciences arena for many years to come. Arguably, the court seesawed by strengthening patent protection in one opinion while weakening patent protection in the other by declaring that certain discoveries cannot be patented. Nonetheless, the court has provided valuable guidance to those who seek patent protection, and a close inspection of these two opinions — Association for Molecular Pathology v. Myriad Genetics Inc., 133 S. Ct. 2107 (2013), and Bowman v. Monsanto Co., 133 S. Ct. 1761, rehearing denied, 2013 WL 3778991 (2013) — reveals that the court has adhered to the principle that innovation should be rewarded.
Patent Eligibility
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
